Targeting transcription-coupled nucleotide excision repair overcomes resistance in chronic lymphocytic leukemia

Trabectedin: Supportive care strategies and safety profile

(2015) Karin Jordan et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Nucleotide excision repair in humans

(2015) Graciela Spivak   DNA REPAIR

Advances in first-line treatment of chronic lymphocytic leukemia: current recommendations on management and first-line treatment by the German CLL Study Group (GCLLSG)

(2015) Paula Cramer et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Nucleotide Excision Repair and Transcription-coupled DNA Repair Abrogate the Impact of DNA Damage on Transcription

(2015) Aditi Nadkarni et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial

(2015) Mohammed Z H Farooqui et al.   LANCET ONCOLOGY

The regulatory interaction of EVI1 with the TCL1A oncogene impacts cell survival and clinical outcome in CLL

(2015) E Vasyutina et al.   LEUKEMIA

Organometallic nucleosides induce non-classical leukemic cell death that is mitochondrial-ROS dependent and facilitated by TCL1-oncogene burden

(2015) Christian Prinz et al.   Molecular Cancer

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

(2015) Dung T. Le et al.   NEW ENGLAND JOURNAL OF MEDICINE

Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents?

(2014) P. Dreger et al.   BLOOD

Trabectedin, a drug acting on both cancer cells and the tumour microenvironment

(2014) M D’Incalci et al.   BRITISH JOURNAL OF CANCER

A C. elegans homolog of the Cockayne syndrome complementation group A gene

(2014) Vipin Babu et al.   DNA REPAIR

Randomised phase III trial of trabectedin versus doxorubicin-based chemotherapy as first-line therapy in translocation-related sarcomas

(2014) Jean-Yves Blay et al.   EUROPEAN JOURNAL OF CANCER

DAF-16/FOXO and EGL-27/GATA promote developmental growth in response to persistent somatic DNA damage

(2014) Michael M. Mueller et al.   NATURE CELL BIOLOGY

Transcription Restores DNA Repair to Heterochromatin, Determining Regional Mutation Rates in Cancer Genomes

(2014) Christina L. Zheng et al.   Cell Reports

Role of Macrophage Targeting in the Antitumor Activity of Trabectedin

(2013) Giovanni Germano et al.   CANCER CELL

Evolution and Impact of Subclonal Mutations in Chronic Lymphocytic Leukemia

(2013) Dan A. Landau et al.   CELL

Mutational heterogeneity in cancer and the search for new cancer-associated genes

(2013) Michael S. Lawrence et al.   NATURE

Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia

(2013) John C. Byrd et al.   NEW ENGLAND JOURNAL OF MEDICINE

Stromal cells modulate TCL1 expression, interacting AP-1 components and TCL1-targeting micro-RNAs in chronic lymphocytic leukemia

(2012) M Sivina et al.   LEUKEMIA

Killing of Chronic Lymphocytic Leukemia by the Combination of Fludarabine and Oxaliplatin Is Dependent on the Activity of XPF Endonuclease

(2011) A. Zecevic et al.   CLINICAL CANCER RESEARCH

Synergistic effects of combination with fludarabine and carboplatin depend on fludarabine-mediated inhibition of enhanced nucleotide excision repair in leukemia

(2011) Kazutaka Takagi et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Cancer Selective Metallocenedicarboxylates of the Fungal Cytotoxin Illudin M

(2011) Rainer Schobert et al.   JOURNAL OF MEDICINAL CHEMISTRY

Enhanced Nucleotide Excision Repair in Human Fibroblasts Pre-exposed to Ionizing Radiation

(2011) Patricia Cramers et al.   PHOTOCHEMISTRY AND PHOTOBIOLOGY

The Syk inhibitor fostamatinib disodium (R788) inhibits tumor growth in the E - TCL1 transgenic mouse model of CLL by blocking antigen-dependent B-cell receptor signaling

(2010) M. Suljagic et al.   BLOOD

Trabectedin Plus Pegylated Liposomal Doxorubicin in Recurrent Ovarian Cancer

(2010) Bradley J. Monk et al.   JOURNAL OF CLINICAL ONCOLOGY

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

(2010) M Hallek et al.   LANCET

Melanoma-specific ferrocene esters of the fungal cytotoxin illudin M

(2009) Sebastian Knauer et al.   ANTI-CANCER DRUGS

High TCL1 levels are a marker of B-cell receptor pathway responsiveness and adverse outcome in chronic lymphocytic leukemia

(2009) M. Herling et al.   BLOOD

The microenvironment in mature B-cell malignancies: a target for new treatment strategies

(2009) J. A. Burger et al.   BLOOD

Efficacy and Safety of Trabectedin in Patients With Advanced or Metastatic Liposarcoma or Leiomyosarcoma After Failure of Prior Anthracyclines and Ifosfamide: Results of a Randomized Phase II Study of Two Different Schedules

(2009) George D. Demetri et al.   JOURNAL OF CLINICAL ONCOLOGY

Persistent transcription-blocking DNA lesions trigger somatic growth attenuation associated with longevity

(2009) George A. Garinis et al.   NATURE CELL BIOLOGY

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

(2008) M. Hallek et al.   BLOOD

Influence of irofulven, a transcription-coupled repair-specific antitumor agent, on RNA polymerase activity, stability and dynamics in living mammalian cells

(2008) A. E. Escargueil et al.   JOURNAL OF CELL SCIENCE

Age to survive: DNA damage and aging

(2008) Björn Schumacher et al.   TRENDS IN GENETICS